The prognostic value of tumor PD-L1 status in patients with metastatic prostate cancer
| Autor: | V. B. Matveev, A. A. Kirichek, V. M. Safronova, N. V. Kokosadze, O. A. Khalmurzaev, B. Sh. Kamolov, L. N. Liubchenko |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Oncology
medicine.medical_specialty Urology metastatic prostate cancer survival Androgen deprivation therapy Prostate cancer pd-l1 Internal medicine Pancreatic cancer medicine Radiology Nuclear Medicine and imaging Lung cancer hormonal therapy business.industry Hazard ratio Cancer poor prognosis medicine.disease Nephrology time to castration resistance biomarker Medicine Hormonal therapy Biomarker (medicine) Surgery business |
| Zdroj: | Onkourologiâ, Vol 15, Iss 1, Pp 57-65 (2019) |
| ISSN: | 1996-1812 1726-9776 |
| Popis: | Background. New potential biomarker for patients with metastatic hormone-naive prostate cancer (PCa) might be detection of programmed death ligand 1 (PD-L1) expression in tumor which is associated with worsened results of treatment and decreased survival in patients with pancreatic cancer, lung cancer and other malignant tumors. Objective : to evaluate the prognostic value of positive tumor PD-L1 status on time to castration resistance (CRPCa) in patients with metastatic PCa receiving hormonal androgen deprivation therapy in first-line systemic treatment. Materials and methods. A total of 35patients with metastatic hormone-naive PCa receiving androgen deprivation therapy with luteinizing hormone-releasing hormone analogue and follow-up at N.N. Blokhin National Medical Research Center of Oncology were recruited in our prospective study. Tumor features of all patients were evaluated for PD-L1 expression on tumor cells by immunohistochemical studies of paraffin block sections obtained under the visual control of the pathologist using a set of monoclonal anti-PD-L1 antibody (28-8) (ab 205921) and Ventana BenchMark GXSlide staining system. Tumor tissue was obtained before starting androgen deprivation therapy. The expression level of PD-L1 >1 % in tumor cells was taken for the positive tumor PD-L1(+) status. Results . Median follow-up was 32.8 months. Positive tumor PD-L1(+) status was identified in 10 (28.6 %) cases. Median time to CRPCa was significantly lower in patients with PD-L1(+) status, than in negative PD-L1(—) status (21.44 vs. 49.12, p = 0.006 log rank test). Multivariate Cox regression analysis confirmed independence prognostic value of PD-L1(+) associated with decreased time to CRPCa (hazard ration 5.95, 95 % confidence interval 1.97—17.99; p = 0.002), including in subgroup of patients with low-volume metastatic disease (hazard ration 7.33, 95 % confidence interval 1.81—29.60; p = 0.005). Discussion . Interaction of PD-1 receptors and its ligands PD-L1/PD-L2 is the key mechanism causing tumor immune escape and progression of the cancer. There are discussed certain ways of inducing PD-L1 expression and its prognostic value on aggressive nonmetastatic PCa. High frequency of positive PD-L1 status was revealed in rare histological subtypes of PCa associated with unfavorable prognosis and visceral metastasis. Conclusion. The results of our study demonstrated the positive tumor PD-L1 status as an independent unfavorable prognostic factorfor patients with metastatic hormone-naive PCa associated with decreased time to castration resistance, including in patients with low volume metastatic disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|